By Pat Anson, Editor
The Food and Drug Administration has notified Zogenix Inc. (NASDAQ: ZGNX) that it won’t reach a final decision on the company’s powerful new painkiller, Zohydro, until this summer.
“To our knowledge this sort of delay is unprecedented,” Roger Hawley, CEO of Zogenix, said during a conference call announcing the company’s first quarter results.
The FDA had already informed Zogenix in late February that it would be unable to reach a decision by a March 1 target date. The agency gave no explanation for the added delay.
Read more at National Pain Report.
(0) Readers Comments
November 12, 2012
October 08, 2012
September 12, 2012
July 23, 2012
June 11, 2019
April 05, 2019
April 01, 2019
March 18, 2019
Oh boy...Your right we hate to hear this. You know why people in pain
Doesn't the 1.5 billion is spent a year give credence to its possitive
Many MS drugs cause PML and deaths too these drugs all need t
I knew him when he was breaking in at a couple of Los Angeles TV stati
Saying there is a 'twist' is the worst type of spoile